tiprankstipranks

CG Oncology initiated with an Overweight at JPMorgan

JPMorgan initiated coverage of CG Oncology (CGON) with an Overweight rating and $41 price target The company is developing the first oncolytic viral therapy to treat non-muscle invasive bladder cancer, the analyst tells investors in a research note. The firm believes CG’s lead asset, Cretostimogene, is well positioned as a “strong player in the evolving” bladder- sparing treatment landscape amid the shortage of Bacillus Calmette-Guerin.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

1